DISCOUNT ZERTIFIKAT - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 01:10:19 29/06/2024 am IST | ||
| 318.2 EUR | -0.00% |
|
| Current month | +1.74% | ||
| 1 month | +1.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 318.2 | -0.00% |
| 27/24/27 | 318.2 | -0.26% |
| 26/24/26 | 319 | +0.40% |
| 25/24/25 | 317.8 | +0.22% |
| 24/24/24 | 317.1 | -0.37% |
Delayed Quote Deutsche Boerse AG
Last update June 29, 2024 at 01:10 am IST
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC0N04 |
| ISIN | DE000PC0N045 |
| Date issued | 03/04/2023 |
| Maturity | 20/12/2024 (175 Days) |
| Parity | 1 : 1 |
| Emission price | 255.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 319.1 € |
|---|---|
| Lowest since issue | 260.7 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Certificates
- Certificat
